Market Intelligence, Clinical Progress, and High-Purity Reagents for Myotonic Dystrophy Type 1 (DM1) and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DMPK drug discovery, supporting oligonucleotide, gene editing, and AOC (Antibody-Oligonucleotide Conjugate) modalities. Select your component below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DMPK Recombinant Protein (Full-length & Kinase Domain). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View DMPK Products |
| Gene Delivery | DMPK Lentivirus Premade Particles. Full-length ORF for stable cell line construction. HEK293 expressed. | View DMPK Products |
| Benchmark Ab | Anti-DMPK Antibody. Recombinant positive control for western blot and knockdown verification. | View DMPK Products |
| Validator | DMPK siRNA Set. For highly specific knockdown verification and control experiments. | View DMPK Products |
| Related Target A | MBNL1 (Muscleblind-Like 1). Downstream effector sequestered by toxic RNA; rescue assay partner. | View MBNL1 Products |
| Related Target B | CNBP (Cellular Nucleic Acid Binding Protein). Associated with DM2 pathology; comparative toxic RNA studies. | View CNBP Products |
| Related Target C | SIX5. Transcriptional partner in DMPK pathway; epistasis analysis. | View SIX5 Products |
| Related Target D | TfR1 (Transferrin Receptor 1). Crucial for AOC-mediated muscle delivery and internalizing ASO/siRNA. | View TfR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Kinase Selectivity Profiling (Avoiding off-target toxicity) | High-purity DMPK Kinase Domain (>95% purity) with ATP-binding site intact; suitable for selectivity panels vs. AGC kinase family. |
| Cellular Rescue Model Construction | Full-length DMPK Lentivirus with native regulatory elements; HEK293 expressed for stable integration in DM1 cellular models. |
| Mechanism Validation (Loss vs. Gain of function) | Matched siRNA and overexpression lentivirus for orthogonal validation. |
| Toxic RNA Binding Assay Controls | Sequence-verified MBNL1 protein for CUG repeat binding competition studies. |
| AOC Delivery Vector Optimization | High-purity TfR1 ECD proteins for internalization and affinity binding assays. |
| Knockdown Specificity Evaluation | Homolog panel proteins strictly verified by mass spec; validated siRNA panels. |
| False Positives in Off-target Screens | HEK293 Expressed native glycosylation proteins ensuring structural fidelity. |
Live DMPK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape for DMPK-related Myotonic Dystrophy Type 1 is currently bifurcating between RNA-targeting strategies (antisense oligonucleotides, small molecule RNA binders, AOCs) and downstream kinase inhibition approaches. First-generation antisense therapies directly target the toxic CUG-repeat RNA, while emerging kinase inhibitor programs focus on modulating DMPK-dependent pathogenic signaling cascades affecting muscle homeostasis. Major players like Avidity Biosciences, Dyne Therapeutics, and Ionis Pharmaceuticals are pioneering Antibody-Oligonucleotide Conjugates (AOCs) to overcome the historical challenge of delivering ASOs and siRNAs to skeletal and cardiac muscle tissues. As the field advances, combination approaches utilizing AOCs for muscle-specific delivery are gaining traction, necessitating robust intracellular target engagement assays and cross-species validation tools to support CNS and skeletal muscle penetration studies. The next wave of R&D is heavily focused on allele-selective silencing, CRISPR/Cas9 editing of the expanded repeats, and optimized muscle-penetrating delivery platforms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Oligonucleotide Conjugate (AOC) | Avidity Biosciences, Dyne Therapeutics | Myotonic Dystrophy Type 1 (Muscle) | Cell-based uptake assays requiring DMPK-overexpressing stable cell lines (Lentivirus-delivered) |
| Small Molecule (RNA Binder) | LoQus23 Therapeutics, Expansion Therapeutics, University of Rochester | DM1 (Systemic) | Competition binding assays with CUG-repeat RNA; need high-purity DMPK for non-specific binding controls |
| Kinase Inhibitor | Preclinical programs | DM1 (Cardiac/CNS) | Enzymatic activity assays with DMPK Kinase Domain; selectivity panels vs. ROCK/PKA family kinases |
| Gene Editing (CRISPR) | Vertex Pharmaceuticals, various academic consortia | DM1 (Germline/Somatic) | Rescue assay controls using DMPK mutant proteins (kinase-dead variants) |
| ASO / siRNA | Ionis Pharmaceuticals, Arrowhead | Neuromuscular Disorders | Knockdown Validation (Need accurate DMPK benchmark Abs & siRNAs) |
Key Molecular Differentiation Factors
- Affinity & Selectivity: DMPK belongs to the AGC kinase family; high homology with ROCK1/2 and PKA necessitates >100-fold selectivity. High-purity DMPK kinase domain with intact DFG-in conformation is critical for high-content screening.
- Delivery & Tissue Penetration: BBB penetration models require human DMPK-overexpressing endothelial cell lines (Lentivirus-constructed). AOC delivery relies on TfR1-interacting affinity in the nM range to avoid affinity sink.
- Mechanism Validation: Distinguishing RNA binders from kinase inhibitors demands robust loss-of-function controls: DMPK siRNA, CRISPR knockout lines, and kinase-dead mutant overexpression.
- Safety & Cardiotoxicity: DMPK is highly expressed in myocardium; parallel hERG screening combined with DMPK target-specific assays is essential.